Board of Directors

Guiding a prosperous tomorrow

The Genmab Board of Directors is composed of a diverse group of industry experts with a deep understanding in life sciences and corporate governance. As current or former chief executive officers, presidents and leaders in their respective fields, our board of directors offers Genmab extensive experience from international research-based organizations, including leading biotech and pharmaceutical companies.

The Genmab Board of Directors meets several times a year for ordinary or extraordinary meetings. Board duties include overseeing the business strategy, accounting practices, executive compensation, corporate governance practices and the appointment of executive officers. The Board of Directors has established four committees: the Compensation Committee, the Audit and Finance Committee, the Scientific Committee and the Nominating and Corporate Governance Committee.

In accordance with the articles of association, the Board of Directors is elected partly by the Annual General Meeting (AGM) and partly by Genmab employees. Board members elected by the AGM are elected for a period of one year whereas board members elected by Genmab employees are elected for a period of three years. Members may stand for re-election for successive terms. The Board of Directors shall consist of not less than three and no more than nine members elected by the AGM. Currently the Board of Directors is comprised of nine members including the three employee representatives.

The business address for the members of the Board of Directors is c/o Genmab A/S, Carl Jacobsens Vej 30, 2500 Valby, Denmark.

Gender Composition in the Board of Directors

At the General Meeting of Genmab A/S, the Board of Directors proposes election of the most suitable candidates based on, amongst other criteria, the skill set requirements for board of directors of biotechnology companies. In connection with the proposals for election, the Board of Directors takes into consideration the opportunity to propose election of candidates that may secure gender equality to the Board of Directors for the long term.

With the current shareholder-elected board members being evenly split between male and female, the Board of Directors’ current composition constitutes equal gender representation in accordance with the guidelines from the Danish Business Authority. It is the Board of Directors’ aim to maintain an equitable gender representation in the Board of Directors.




Learn more about our board members by clicking on their names.

Deirdre P. Connelly

Board Chair

Independent

Elected by: General Meeting

First elected: 2017
Current term expires: 2024

Committee Positions

Chair: Nominating & Corporate Governance

Member: Audit & Finance, Compensation

Nationality

Hispanic/American

Born

October 1960

Special Competencies

Deirdre P. Connelly has more than 30 years’ experience as a corporate leader and board member in publicly traded companies with global operations. She has comprehensive knowledge and experience with business turnaround and product development and has successfully directed the launch of more than 20 new pharmaceutical drugs. As a former HR executive, Deirdre P. Connelly also has valuable insight in corporate culture transformation, talent development and managing large organizations. She furthermore has significant experience with the development of governance and ESG responsibilities from various leadership roles and as a board member. Deirdre P. Connelly is former President of U.S. Operations of Eli Lilly and Company and former President, North America Pharmaceuticals for GlaxoSmithKline.

Current Board Positions

Member: Lincoln Financial Corporation1, Macy’s Inc.2

1. Chair of Corporate Governance Committee, Member of Audit Committee
2. Chair of Nominating and Governance Committee, Member of Compensation and Management Development Committee

Pernille Erenbjerg

Deputy Chair

Independent
Elected by: General Meeting
First elected: 2015
Current term expires: 2024

Committee Positions

Chair: Audit & Finance Committee
Member: Nominating & Corporate Governance

Nationality

Danish

Born

August 1967

Special Competencies

Pernille Erenbjerg has broad executive management and business experience from the telecoms, media and tech industries. She has extensive expertise in operation and strategic transformation of large and complex companies, including digital transformations and digitally based innovation, and has been responsible for major transformation processes in complex organizations including M&A. Pernille Erenbjerg furthermore has significant IT and cybersecurity expertise and ESG experience from various executive and non-executive positions. She has a Certified Public Accountant background (no longer practicing) and has a comprehensive all-around background within finance, including extensive exposure to public and private equity and debt investors. Pernille Erenbjerg is former CEO and President of TDC Group A/S. Pernille Erenbjerg is an audit committee financial expert based on her professional experience, including her background within accounting, her service in senior finance leadership at TDC Group A/S and as an audit committee chair or member at other public companies.

Current Board Positions

Chair: KK Wind Solutions
Deputy Chair: Millicom1
Member: RTL Group2, GlobalConnect

1. Chair of Compensation Committee
2. Chair of Audit Committee

Anders Gersel Pedersen, M.D., Ph.D.

Board Member

Non-independent
Elected by: General Meeting
First elected: 2003
Current term expires: 2024

Committee Positions

Chair: Compensation
Member: Scientific, Nominating & Corporate Governance

Nationality

Danish

Born

September 1951

Special Competencies

Anders Gersel Pedersen has more than 30 years’ board and management experience in publicly traded, international pharmaceutical and biotech companies. He has significant knowledge and expertise in discovery and development of the product pipeline from preclinical activities to post-launch marketing studies as well as solid business experience. Anders Gersel Pedersen furthermore has extensive experience with the global pharmaceutical market and has built comprehensive knowledge and insight in governance and the development of ESG responsibilities from various leadership roles and as a board member. Anders Gersel Pedersen is former Executive Vice President of Research & Development of H. Lundbeck.

Current Board Positions

Chair: Aelis Farma S.A.S.
Deputy Chair: Bavarian Nordic A/S1
Member: Hansa Biopharma AB2, Bond 2 Development 2 GP Limited

1. Member of Nomination and Compensation Committee, Member of Science, Technology & Investment Committee
2. Chair of Scientific Committee, Member of Remuneration Committee

Paolo Paoletti, M.D.

Board Member

Independent
Elected by: General Meeting
First elected: 2015
Current term expires: 2024

Committee Positions

Chair: Scientific
Member: Compensation

Nationality

Italian /American

Born

October 1950

Special Competencies

Paolo Paoletti has extensive experience in research, development and commercialization in the pharmaceutical industry, where he has been responsible for the development of several medicines approved globally and the related global commercial strategies. As an executive, he has led cross-functional teams on the development and registration of medicines and has been responsible for all compliance aspects for the R&D organization. Paolo Paoletti has successfully conducted submissions and approvals of new cancer drugs and new indications in the U.S., in Europe and in Japan. He furthermore has significant experience with governance from various leadership roles and as a board member. Paolo Paoletti is former Vice President of Oncology Clinical Development with Eli Lilly and Company, former President of GSK Oncology with GlaxoSmithKline and former CEO of GAMMADELTA Therapeutics.

Current Position, including Managerial Positions

Member of the Investment Committee for Apollo Therapeutics Limited
Scientific Advisor for 3B Future Health Fund

Rolf Hoffmann

Board Member

Independent
Elected by: General Meeting
First elected: 2017
Current term expires: 2024

Committee Positions

Member: Audit & Finance, Scientific

Nationality

German

Born

May 1959

Special Competencies

Rolf Hoffmann has more than 30 years’ experience in senior management and as a board member in the life science industry worldwide. He has significant expertise in creating and optimizing commercial opportunities in global markets and has managed companies across multiple continents with multibillion P&L and cross-functional accountability. Rolf Hoffmann furthermore has knowledge and experience with governance, compliance and ensuring organizational efficiency from various management positions as well as from being a board member. Rolf Hoffmann has held a variety of sales and marketing and executive management positions with Eli Lilly and Company, and is former Senior Vice President, International Commercial Operations and former Senior Vice President, U.S. Commercial Operations with Amgen.

Current Position, including Managerial Positions

Adjunct Professor Strategy and Entrepreneurship, University of North Carolina Business School

Current Board Positions

Member: IDT Biologika, Semdor Pharma and Sun Pharmaceutical Industries Ltd. 

Elizabeth O’Farrell

Board Member

Independent
Elected by: General Meeting
First elected: 2022
Current term expires: 2024

Committee Positions

Member: Audit & Finance, Compensation

Nationality

American

Born

April 1964

Special Competencies

Elizabeth O’Farrell has solid financial experience from her 25-year career in finance leadership roles and as a board member. During her career, she has led multiple strategy, planning and resource allocation processes in multiple roles and in cross-functional teams. Elizabeth O’Farrell has significant knowledge and expertise with driving paradigm changing contributions within finance and the enterprise through collaboration and influence. In addition to experience at Price Waterhouse and Whipple & Company Corporation, Elizabeth O’Farrell held various executive management positions at Eli Lilly and Company, including as former Chief Procurement Officer. Elizabeth O’Farrell is an audit committee financial expert based on her professional experience, including her service in senior finance leadership positions at Eli Lilly and as an audit committee chair or member at other public companies.

Current Board Positions

Chair: PDL BioPharma
Member: LENSAR1, Geron Corporation1, Karius1

1. Chair  of Audit Committee

Takahiro Hamatani

Board Member

Non-independent
Elected by: Employees
First elected: 2022
Current term expires: 2025

Nationality

Japanese

Born

March 1974

Special Competencies

Takahiro Hamatani has over 20 years’ experience in the pharmaceutical industry in various roles including finance, sales, marketing and corporate strategy. He has extensive expertise in strategic business planning and finance business partnering as well as experience in successful product launches, geographical expansions, and business development deals. Takahiro Hamatani has previously worked in International Operations at Takeda supporting commercial operations in North and South America and is a Certified Public Accountant in the US.

Current Position, including Managerial Positions

Senior Director, Finance Japan at Genmab

Martin Schultz

Board Member

Non-independent
Elected by: Employees
First elected: 2022
Current term expires: 2025

Nationality

Danish

Born

September 1975

Special Competencies

Martin Schultz has broad experience within clinical project management with a substantial understanding and knowledge of research and development. He furthermore has specific expertise in project management, strategic sourcing, vendor collaboration, contract and budget governance.

Current Position, including Managerial Positions

Senior Director, Head of Development Business Partnership & Strategy at Genmab

Mijke Zachariasse, Ph.D.

Board Member

Non-independent
Elected by: Employees
First elected: 2019
Current term expires: 2025

Nationality

Dutch

Born

August 1973

Special Competencies

Mijke Zachariasse has broad experience in people and business management and expertise in building partnerships across sectors, research funding landscape, operational excellence and organizational strategy and change.

Current Position, including Managerial Positions

Vice President, Head of Antibody Research Materials at Genmab

Committee Composition

Board Diversity and Skills Matrix

Basic InformationCore Skills
DirectorBornGender and NationalityLife Science
Industry
Executive
Experience
Financial/
Risk
Legal/
Governance
IT/Tech/
Cybersecurity
Environmental/
Sustainability
International
Markets
Scientific/
R&D

Employee ElectedSwipe to view moreScroll to view more

Evaluation

No less than once a year the Board of Directors evaluates its performance and achievements as well as the individual board members’ respective work and results.

The Chair of the Board of Directors ensures that the Board of Directors performs regular assessments of its own performance to verify that the Board of Directors is capable of fulfilling its function and responsibilities, and that the outcome of such evaluations are discussed with the Board of Directors. When performing these evaluations external assistance is obtained every year. The evaluation is based upon anonymous questionnaires on the work in the Board of Directors, the work in the board committees, the cooperation with the Executive Management, anonymous evaluation of the individual board members and an interview with an external consultant with each member of the Board of Directors and the Executive Management. Furthermore, the Board of Directors performs regular assessments of the Executive Management and of the collaboration between the parties to identify any areas in potential need of improvement.

In 2023, the Board of Directors’ self-assessment consisted of a questionnaire survey combined with one-to-one interviews with each member of the Board of Directors and the Executive Management facilitated by an external consultant. As part of the 2023 self-assessment, each board committee evaluated its role, mandate, responsibilities and the tasks carried out.

The outcome of the Board of Directors’ 2023 self-assessment was positive with only minor areas for improvement identified. Overall, there was a high degree of satisfaction with the board meetings and the collaboration in the Board of Directors and very good feedback to the board committees and to the chair of the Board of Directors. The competencies in the Board of Directors were considered in general to be adequate and well balanced, and it was the assessment that the Board of Directors currently has the right size. The attention to strategy and organizational themes was perceived to be at a high level and there was confidence in the present strategy and the execution thereof. Also, there was a perception that the Board of Directors’ attention to ESG, IT and cybersecurity is at a good level, and that there is a high level of compliance with legal responsibilities and good corporate governance principles. It was further concluded that the interface between the Board of Directors and the Executive Management continued to be very strong and that an excellent relationship exists between the Executive Management and the Board of Directors.

Want to get the latest stock information and news about Genmab?

Start here

  • Sound corporate governance

    Our corporate governance is at the center of everything we do

    Learn more

  • Being socially responsible

    We are building a sustainable company through business-driven CSR

    Learn about our CSR

  • Turning insights into medicine

    See the results of innovation that is rooted in science

    Explore the pipeline

You are now leaving Genmab.com to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.